A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. / Rasmussen, Anne-Sofie Schrohl; Mueller, Volkmar; Christensen, Ib Jarle; Pantel, Klaus; Thomssen, Christoph; Brunner, Nils.

In: Tumor Biology, Vol. 29, No. 3, 2008, p. 181-187.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Rasmussen, A-SS, Mueller, V, Christensen, IJ, Pantel, K, Thomssen, C & Brunner, N 2008, 'A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer', Tumor Biology, vol. 29, no. 3, pp. 181-187. https://doi.org/10.1159/000146863

APA

Rasmussen, A-S. S., Mueller, V., Christensen, I. J., Pantel, K., Thomssen, C., & Brunner, N. (2008). A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. Tumor Biology, 29(3), 181-187. https://doi.org/10.1159/000146863

Vancouver

Rasmussen A-SS, Mueller V, Christensen IJ, Pantel K, Thomssen C, Brunner N. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. Tumor Biology. 2008;29(3):181-187. https://doi.org/10.1159/000146863

Author

Rasmussen, Anne-Sofie Schrohl ; Mueller, Volkmar ; Christensen, Ib Jarle ; Pantel, Klaus ; Thomssen, Christoph ; Brunner, Nils. / A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. In: Tumor Biology. 2008 ; Vol. 29, No. 3. pp. 181-187.

Bibtex

@article{8dc09f70c51111dd8ca2000ea68e967b,
title = "A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer",
abstract = "OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p < 0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.",
author = "Rasmussen, {Anne-Sofie Schrohl} and Volkmar Mueller and Christensen, {Ib Jarle} and Klaus Pantel and Christoph Thomssen and Nils Brunner",
note = "Keywords: Adult; Aged; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Tissue Inhibitor of Metalloproteinase-1; Tumor Markers, Biological",
year = "2008",
doi = "10.1159/000146863",
language = "English",
volume = "29",
pages = "181--187",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

AU - Rasmussen, Anne-Sofie Schrohl

AU - Mueller, Volkmar

AU - Christensen, Ib Jarle

AU - Pantel, Klaus

AU - Thomssen, Christoph

AU - Brunner, Nils

N1 - Keywords: Adult; Aged; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Tissue Inhibitor of Metalloproteinase-1; Tumor Markers, Biological

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p < 0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.

AB - OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p < 0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.

U2 - 10.1159/000146863

DO - 10.1159/000146863

M3 - Journal article

C2 - 18645261

VL - 29

SP - 181

EP - 187

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 3

ER -

ID: 8933461